Researchers sought to determine whether combination therapies with carfilzomib would be feasible for patients with relapsed/refractory multiple myeloma.
A retrospective study revealed age-based risks for toxicities in patients with NHL treated with high-dose chemotherapy and autologous hematopoietic cell transplantation.
Researchers sought to determine the real-world renal function and outcomes for patients with multiple myeloma according to type of treatment and line of therapy.
Researchers sought to determine whether poorer health-related quality of life would be linked to responses about pain severity in patients with multiple myeloma.
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
Researchers compared outcomes in patients with PCNSL who did not meet clinical trial criteria with those of patients from a major multicenter clinical trial of PCNSL.
A chemoimmunotherapy regimen with only 3 cycles of chemotherapy was found to be efficacious in a phase 2 trial that sought to reduce treatment-related MDS/AML in patients with CLL.
